FDA Approves Moderna's RNA RSV Vaccine for Older Adults

The vaccine, mRESVIA, is the first mRNA-based RSV shot and the second product from Moderna to receive FDA approval.

Moderna's RSV vaccine shows 83.7% efficacy in preventing lower respiratory tract disease in phase 3 trials.
This approval marks the first mRNA vaccine for a disease other than COVID-19.
The vaccine is designed for ease of administration with a pre-filled syringe, reducing potential errors.
RSV poses significant risks to older adults, leading to thousands of hospitalizations and deaths annually.
Moderna aims to have the vaccine available for the 2024-2025 RSV season, pending CDC recommendations.